Drug Approval | June 27, 2024
Shilpa Medicare Bio Analytical unit gets "No Action Indicated" classification from USFDA
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
This Unit of Shilpa Medicare is engaged in testing biological samples of clinical studies
Signs MoUs with Shri Krishna Ayush University and Dabur India
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
First immunotherapy regimen before and after surgery to extend survival in bladder cancer
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
The facility was inspected from May 7 to May 17, 2024
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Combined entity is better positioned to compete in increasingly competitive generics industry
PEKK is a high-performance polymer family used in aerospace and other demanding markets
Subscribe To Our Newsletter & Stay Updated
